{"organizations": [], "uuid": "9786b25cdbc60c8f4343a8e1441a14bcb27bbc18", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180220.html", "section_title": "Archive News &amp; Video for Tuesday, 20 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-dynavax-secures-175-million-in-non/brief-dynavax-secures-175-million-in-non-dilutive-debt-financing-idUSASB0C6BV", "country": "US", "domain_rank": 408, "title": "BRIEF-Dynavax Secures $175 Million In Non-Dilutive Debt Financing", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.469, "site_type": "news", "published": "2018-02-20T19:59:00.000+02:00", "replies_count": 0, "uuid": "9786b25cdbc60c8f4343a8e1441a14bcb27bbc18"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-dynavax-secures-175-million-in-non/brief-dynavax-secures-175-million-in-non-dilutive-debt-financing-idUSASB0C6BV", "ord_in_thread": 0, "title": "BRIEF-Dynavax Secures $175 Million In Non-Dilutive Debt Financing", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "dynavax", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "dynavax technologies corp", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - Dynavax Technologies Corp:\n* DYNAVAX SECURES $175 MILLION IN NON-DILUTIVE DEBT FINANCING\n* DYNAVAX TECHNOLOGIES - TO RECEIVE $100 MILLION IN A FIRST TRANCHE AND UP TO AN ADDITIONAL $75 MILLION MAY BE BORROWED IN A SECOND TRANCHE AT DYNAVAX‘S OPTION​\n* DYNAVAX TECHNOLOGIES SAYS CASH POSITION WILL SUPPORT LAUNCH OF HEPLISAV-B FIELD SALES TEAM NEXT WEEK AND PHASE 3 CLINICAL TRIAL OF SD-101 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-20T19:59:00.000+02:00", "crawled": "2018-02-21T21:16:17.043+02:00", "highlightTitle": ""}